Accepted for Publication: August 30, 2023.
Corresponding Author: Andrew A. Nierenberg, MD, Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, 50 Staniford St, Suite 580, Boston, MA 02114 (anierenberg@mgh.harvard.edu).
Conflict of Interest Disclosures: Dr Nierenberg reported serving on an adjudication committee for Novartis; consulting for Alkermes, Clexio, Ginger/Headspace Health, Janssen, Merck, Neuronetics, NeuroRx, Otsuka, Protagenics, SAGE, Sunovion, and Unravel Bioscience; receiving honoraria from Belvior, EISAI, Psychiatric Annals Slack Publications, Wiley Depression and Anxiety, Guilford Publications, and Up-to-Date Wolters Kluwer Health; and serving on a scientific advisory board for Altimate, Flow, Milken Center for Strategic Philanthropy, Myriad, and 4M Therapeutics outside the submitted work. Dr Cusin reported receiving grants from Janssen, Otsuka, Clexio, and Shenox and personal fees from Perception and serving on a data and safety monitoring board for Alkermes outside the submitted work. Dr Sylvia reported receiving personal fees from New Harbinger and grants from PCORI and NIMH outside the submitted work. Dr Berk is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072) and reported receiving grant/research support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant, and the Harry Windsor Foundation; serving as a speaker for AstraZeneca, Lundbeck, Merck, and Pfizer; and serving as a consultant to Allergan, AstraZeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer, and Servier outside the submitted work. No other disclosures were reported.